Citations

Clear

22 citation(s) found for "Levine, Edward A".

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Murthy, Hemant S. , Zhang, Mei‐Jie , Chen, Karen , Ahmed, Sairah , Ganguly, Siddhartha , Kansagra, Ankit , Michelis, Fotios V. , Nishihori, Taiga , Patnaik, Mrinal M. , Aljurf, Mahmoud , Arai, Yasuyuki , Badar, Talha , Ballen, Karen K. , Bejanyan, Nelli , Brown, Valerie I. , Martino, Rodrigo , Cahn, Jean‐Yves , Castillo, Paul , Černý, Jan , Copelan, Edward A. , Daly, Andrew , Freytes, César O. , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Jamy, Omer , Joseph, Jacinth , Kanakry, Christopher G. , Khera, Nandita , Krem, Maxwell M. , Kuwatsuka, Yachiyo , Lekakis, Lazaros J. , Liu, Hongtao , Modi, Dipenkumar , Munshi, Pashna N. , Palmisiano, Neil , Rizzieri, David A. , Seo, Sachiko , Sharma, Akshay , Sohl, Melhm, Solomon, Scott R. , Ulrickson, Matthew L. , Üstün, Celalettin , Poel, Marjolein van der , Verdonck, Leo F. , Wagner, John L. , Wang, Trent , Wirk, Baldeep , Zeidan, Amer M. , Litzow, Mark R. , Weisdorf, Daniel J. , Saber, Wael , Kharfan‐Dabaja, Mohamed A. , Kansagra, Ankit , Michelis, Fotios V , Nishihori, Taiga , Patnaik, Mrinal , Arai, Yasuyuki , Badar, Talha , Bejanyan, Nelli , Bhatt, Vijaya Raj , Chhabra, Saurabh , Dholaria, Bhagirathbhai R , Diaz Perez, Miguel Angel , Freytes, Cesar O , Hashmi, Shahrukh K , Jamy, Omer , Krem, Maxwell M , Lazarus, Hillard M , Liu, Hongtao , Modi, Dipenkumar , Mussetti, Alberto , Patel, Sagar , Shah, Mithun V , Sharma, Akshay , Ustun, Celalettin , Wagner, John , Litzow, Mark R. , Hourigan, Christopher S , Weisdorf, Dan , Kharfan-Dabaja, Mohamed A , Murthy, Hemant S , Martino, Rodrigo , Ahmed, Sairah , Zeidan, Amer M , Deotare, Uday , Abid, Muhammad Bilal , Bacher, Ulrike , Badawy, Sherif M. , Battiwalla, Minoo , Beitinjaneh, Amer , Bhatt, Vijaya Raj , Chhabra, Saurabh , Dholaria, Bhagirathbhai , Díaz, Miguel Ángel , Grunwald, Michael R. , Lazarus, Hillard M. , Mussetti, Alberto , Patel, Sagar S. , Shah, Meera , Kebriaei, Partow , Hourigan, Christopher S.

Mayo Clinic

Blood Advances | October 4, 2023 | Volume: 7 | Issue: 22 | Pages: 7007-7016

10.1182/bloodadvances.2023011308 | PMID 37792849 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.
Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery
Mangieri, Christopher W. , Moaven, Omeed , Valenzuela, Cristian D. , Votanopoulos, Konstantinos I., Shen, Perry , Levine, Edward A. , Levine, Edward A , W Mangieri, Christopher , Moaven, Omeed , Erali, Richard A.

Mayo Clinic

Journal of Surgical Oncology | November 29, 2021 | Volume: 125 | Issue: 4 | Pages: 703-711

10.1002/jso.26759 | PMID 34841542 Get It

AbstractIntroductionHyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery (CRS) is typically reserved for a complete or optimal cytoreduction. There is the potential for therapeutic effect of HIPEC with an incomplete cytoreduction, particularly for near optimal cytoreductions.MethodsRetrospective review of incomplete cytoreductions (R2b, R2c) for appendiceal and colorectal primaries. Primary endpoints were overall survival (OS) and progression‐free survival (PFS). Subgroup analysis for primary etiology and specific cytoreductive score.ResultsA total of 121 cases of incomplete CRS, 74 CRS alone, and 47 CRS‐HIPEC. For the entire study group there was a survival benefit with HIPEC. OS and PFS were 2.3 versus 1.4 (p = 0.001) and 1.6 versus 0.7 (p < 0.0001) respectively for cases with and without HIPEC. Subgroup analysis of appendiceal neoplasms, 43 CRS‐HIPEC and 50 CRS alone, found HIPEC benefit persisted; OS and PFS were 2.4 versus 1.5 (p = 0.016) and 1.7 versus 0.8 (p < 0.0001), respectively for cases with and without HIPEC. Benefit most pronounced in low‐grade cases with doubling of the OS and PFS (p = 0.004). With colorectal primary cases, 10 CRS‐HIPEC and 18 CRS alone, no difference in OS and PFS. When stratifying out by cytoreduction scores, R2b and R2c, HIPEC only provided a benefit for R2b cases; OS and PFS for R2b cases were 2.28 versus 1.01 (p = 0.011) and 1.67 versus 0.75 (p = 0.001), respectively for cases with and without HIPEC.ConclusionHIPEC has utility for incomplete cytoreductions with appendiceal neoplasms, greatest effect with low‐grade appendiceal neoplasms. HIPEC is only beneficial for near optimal cytoreductions (R2b).
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff, Craig L. , Lewis, Karl D. , Andtbacka, Robert Hans Ingemar, Hyngstrom, John , Milhem, Mohammed , Bowles, Tawnya L. , Hamid, Omid , Hernandez‐Aya, Leonel F. , Claveau, Joël, Jang, Sekwon, Philips, Prejesh, Holtan, Shernan G. , Shaheen, Montaser , Curti, Brendan D. , Schmidt, William, Butler, Marcus O. , Paramo, Juan, Lutzky, Jose , Padmanabhan, Arvinda, Thomas, Sajeve , Milton, Daniel T., Pecora, Andrew L. , Sato, Takami , Hsueh, Eddy C. , Badarinath, Suprith, Keech, John A., Kalmadi, Sujith, Kumar, Pallavi , Weber, Robert, Levine, Edward A. , Berger, Adam C. , Bar, Anna, Travers, Jeffrey B. , Mihalcioiu, Catalin , Gastman, Brian , Beitsch, Peter D. , Rapisuwon, Suthee , McCarron, Edward C. , Gupta, Vinay , Behl, Deepti , Blumenstein, Brent A. , Peterkin, Joanna, Curti, Brendan , Lutzky, Jose , Rapisuwon, Suthee , Milhem, Mohammed M , Butler, Marcus O , Levine, Edward A , Holtan, Shernan , Markovic, Svetomir N. , Paramo, Juan, Milton, Daniel, Beck, J. Thaddeus , Glaspy, John A.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 1, 2021 | Volume: 9 | Issue: 10 | Pages: e003272

10.1136/jitc-2021-003272 | PMID 34599031 Get It

Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. Methods Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. Results For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). Conclusions Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. Trial registration number NCT01546571.
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Wieduwilt, Matthew J. , Metheny, Leland , Zhang, Mei‐Jie , Wang, Hailin , Estrada‐Merly, Noel, Marks, David I. , Al‐Homsi, A. Samer, Muffly, Lori , Chao, Nelson J. , Rizzieri, David A. , Gadalla, Shahinaz M. , Cairo, Mitchell S. , Gore, Steven D. , Patel, Sagar S. , Michelis, Fotios V. , Inamoto, Yoshihiro , Copelan, Edward A. , Palmisiano, Neil , Kharfan‐Dabaja, Mohamed A. , Ganguly, Siddhartha , Bredeson, Christopher , Ballen, Karen K. , Martino, Rodrigo , Wirk, Baldeep , Aljurf, Mahmoud , Bashey, Asad, Murthy, Hemant S. , Farhadfar, Nosha , Liu, Hongtao , Abdel‐Azim, Hisham , Solh, Melhem , Seftel, Matthew D. , Poel, Marjolein van der , Kamble, Rammurti T., Munker, Reinhold , Cahn, Jean‐Yves , Freytes, César O. , Krem, Maxwell M. , Winestone, Lena E. , Nathan, Sunita , Verdonck, Leo F. , Sharma, Akshay , Ringdén, Olle , Černý, Jan , Choe, Hannah , Seo, Sachiko , Baxter‐Lowe, Lee Ann , Hildebrandt, Gerhard , Litzow, Mark R. , Abid, Muhammad Bilal , Weisdorf, Daniel J. , Saber, Wael , Chao, Nelson , Rizzieri, David A , Gadalla, Shahinaz M , Bhatt, Vijaya Raj , Patel, Sagar , Michelis, Fotios V , Kharfan-Dabaja, Mohamed A , Savani, Bipin N , Martino, Rodrigo , Bacher, Ulrike , Liu, Hongtao , Waller, Edmund K , McGuirk, Joseph , Krem, Maxwell M , Winestone, Lena E , Olsson, Richard F , Sharma, Akshay , Ringden, Olov , Friend, Brian D , Cerny, Jan , Chhabra, Saurabh , Nishihori, Taiga , Seo, Sachiko , George, Biju , Baxter-Lowe, Lee Ann , Hildebrandt, Gerhard C , de Lima, Marcos , Litzow, Mark R. , Hourigan, Christopher S , Weisdorf, Dan , Murthy, Hemant S , Muffly, Lori , Abid, Muhammad Bilal , Gale, Robert Peter , Mussetti, Alberto , Bhatt, Vijaya Raj , Badawy, Sherif M. , Lazarus, Hillard M. , Díaz, Miguel Ángel , Cassaday, Ryan D. , Savani, Bipin N. , Yared, Jean A. , Aldoss, Ibrahim , Waller, Edmund K. , Grunwald, Michael R. , Liesveld, Jane L. , McGuirk, Joseph P. , Lee, Jong Wook , Gergis, Usama , Olsson, Richard F. , Chhabra, Saurabh , Nishihori, Taiga , Lima, Marcos de , Kebriaei, Partow , Hourigan, Christopher S.

Mayo Clinic

Blood Advances | September 21, 2021 | Volume: 6 | Issue: 1 | Pages: 339-357

10.1182/bloodadvances.2021004916 | PMID 34547770 Get It

Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P &lt; .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P &lt; .001) and grade 3 to 4 aGVHD (HR, 1.97; P &lt; .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
Zhou, Zheng , Nath, Rajneesh , Černý, Jan , Wang, Hai-Lin, Zhang, Mei-Jie , Abdel‐Azim, Hisham , Agrawal, Vaibhav , Ahmed, Gulrayz , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Battiwalla, Minocher, Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Choe, Hannah , Copelan, Edward A. , Damlaj, Moussab , DeFilipp, Zachariah , Farhadfar, Nosha , Foran, James M. , Freytes, César O. , Gul, Zartash , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Hossain, Nasheed , Inamoto, Yoshihiro , Isola, Luis , Jain, Tania , Kamble, Rammurti T., Khan, Muhammad , Kharfan‐Dabaja, Mohamed A. , Kekre, Natasha , Khera, Nandita , Litzow, Mark R. , Liu, Hongtao , Marks, David I. , Martino, Rodrigo , Mathews, Vikram , Mishra, Asmita , Murthy, Hemant S. , Nagler, Arnon , Nakamura, Ryotaro , Nathan, Sunita , Olin, Rebecca L. , Palmisiano, Neil , Patnaik, Mrinal M. , Pawarode, Attaphol , Politikos, Ioannis , Rizzieri, David A. , Seo, Sachiko , Shah, Nirav N. , Uy, Geoffrey L. , Verdonck, Leo F. , Wang, Youjin , Weisdorf, Daniel J. , Wirk, Baldeep , Saber, Wael , Hashmi, Shahrukh, Jain, Tania , Murthy, Hemant S , Weisdorf, Dan , Martino, Rodrigo , Liu, Hongtao , Mathews, Vikram , Uy, Geoffrey , Ahmed, Gulrayz , Zhang, Mei‐Jie , Alkhateeb, Hassan B. , Assal, Amer , Bacher, Ulrike , Bajel, Ashish R. , Bashir, Qaiser , Battiwalla, Minocher, Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Lima, Marcos de , Díaz, Miguel Ángel , Gerds, Aaron T. , Gergis, Usama , Grunwald, Michael R. , Hamadani, Mehdi , Hertzberg, Mark , Kebriaei, Partow , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Patel, Sagar S. , Perales, Miguel‐Angel , Politikos, Ioannis , Popat, Uday R , Sandmaier, Brenda M , Savani, Bipin N. , Valcárcel, David , Waller, Edmund K. , Wong, Eric Y.L. , Yared, Jean A.

Mayo Clinic

Blood Advances | July 1, 2021 | Volume: 4 | Issue: 13 | Pages: 3180-3190

10.1182/bloodadvances.2019001266 | PMID 32663298 Get It

Abstract There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P &lt; .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P &lt; .001). Long-term relapse was lower with FM (HR = 0.65, P &lt; .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM.
Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood
Wang, Trent , Litzow, Mark R. , Baron, Frédéric , Saad, Ayman , Khera, Nandita , Copelan, Edward A. , DeFilipp, Zachariah , Bredeson, Christopher , Krem, Maxwell M. , Zhang, Mei‐Jie , Chen, Karen , Saber, Wael , Saad, Ayman , Jiménez, Antonio , Lima, Marcos de , Komanduri, Krishna V. , Kebriaei, Partow , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Murthy, Hemant S. , Martino, Rodrigo , Nishihori, Taiga , Weisdorf, Daniel J.

Mayo Clinic

Blood | November 4, 2020 | Volume: 136 | Issue: Supplement 1 | Pages: 27-29

10.1182/blood-2020-137589 Get It

Background: Allogeneic HCT continues to be the optimal consolidation strategy for many patients with AML. Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes. We tested the prognostic ability of a modified (mELN) classification system based on available CIBMTR genetic data, to predict post-transplant outcomes. Methods: Adult patients with a diagnosis of AML in first complete remission (CR1) with available pre-transplant cytogenetic and molecular mutational data, receiving a first allogeneic HCT from 2013-2017, were included. Patients were stratified according to mELN genetic classification in three distinct groups: favorable (Fav), intermediate (IM) and adverse (Adv). Clinical outcomes following HCT were compared among groups after adjusting for significant patient, disease, and transplant-related variables. The primary endpoint was disease free survival (DFS). Secondary endpoints were overall survival (OS), non-relapse mortality (NRM), cumulative incidence of relapse, acute GVHD, and chronic GVHD. Cox proportional hazard models were used to compare endpoints among mELN risk groups, age groups and genetic subsets within the adverse-risk group. Results: Demographic characteristics are summarized in Table 1. 2289 patients (Fav, n=181; IM n=1185; and Adv n=923) met the inclusion criteria. Median follow-up for survivors was 35 months. Importantly, 41% of transplant recipients (n=936) were &gt;60 years, 76% (n=1743) had de novo AML and 48% (n=1111) received a myeloablative conditioning regimen. Univariate analysis (UVA) demonstrated significant differences in 2-year OS (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p&lt;0.001); DFS (Fav: 57.8%, IM: 55.5% and Adv: 45.3; p&lt;0.001) and relapse (Fav: 28%, IM: 27.5% and Adv: 37.5%; p&lt;0.001) There were no significant differences in NRM (p=0.467) or the incidence of acute (p=0.423) and chronic GVHD (p=0.442) among mELN groups. Initial multivariate analysis (MVA) of mELN risk groups indicated that there was no significant difference in clinical outcomes between the Fav and IM risk groups. Thus, these groups were combined for subsequent analyses. Adv risk (vs. Fav/IM) led to significantly worse OS (HR 1.39 [1.24-1.57] p=&lt;0.001), DFS (HR 1.32 [1.18-1.48] p=&lt;0.001), and relapse (HR 1.42 [1.23-1.63] p=&lt;0.001) (Table 2). This mELN classification effectively stratified both younger (&lt;60 y/o) and older (&gt;60 y/o) patients for OS (Adv vs. Fav/IM HR for &lt;60: 1.43 [1.21-1.69] p&lt;0.001; &gt;60: 1.44 [1.21-1.72] p&lt;0.001), DFS (Adv HR for &lt;60: 1.31 [1.12-1.53] p&lt;0.001; &gt;60: 1.41 [1.19-1.66] p&lt;0.001) and relapse (Adv HR for &lt;60: 1.44 [1.20-1.74] p&lt;0.001, &gt;60: 1.42 [1.15-1.76] p=0.001). NRM was higher for older patients (&gt;60 y/o) in both the Fav/IM (HR 1.40 [1.10-1.78] p=0.007) and Adv-risk cohorts (HR 1.59 [1.18-2.13] p=0.002). Genetic subset comparisons within the adverse-risk group showed that patients carrying monosomy 5, del(5q) or monosomy 7 had inferior 2-year OS (42.6%, p&lt;0.001) and DFS (35.2%, p&lt;0.001), as well as higher rates of relapse (45%, p= 0.002) when compared to other patients within the Adv-risk cohort (OS 60%, DFS 50.8%, relapse 33.5%). Conclusion: Stratification using mELN criteria resulted in clear prognostic separation of OS, DFS and relapse in this large cohort of AML patients undergoing allogeneic HCT. While Fav and IM groups had similar OS, DFS and relapse rates; patients in the Adv risk group had the highest risk of relapse and inferior DFS/OS. However, the majority of patients in all cohorts had favorable outcomes for HCT in CR1. Our findings confirm the value of a combined genetic prognostic model in the AML HCT setting and justify the use of this stratification system in future HCT trials. Correlation of genetic subtypes with other important transplant variables, such as conditioning intensity and pre-transplant MRD status deserves further evaluation. There remains a subset of Adv-risk patients for which post-transplant outcomes continue to be poor, even when transplanted in CR1. Novel peri-transplant pre-emptive/therapeutic strategies are urgently needed for this high-risk cohort. Disclosures de Lima: Celgene: Research Funding; Pfizer: Other: Personal fees, advisory board, Research Funding; BMS: Other: Personal Fees, advisory board; Incyte: Other: Personal Fees, advisory board; Kadmon: Other: Personal Fees, Advisory board. Komanduri:Kiadis: Consultancy; Takeda: Consultancy; Celgene: Consultancy; Atara: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptimmune: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kebriaei:Ziopharm: Other: Research Support; Jazz: Consultancy; Kite: Other: Served on advisory board; Amgen: Other: Research Support; Novartis: Other: Served on advisory board; Pfizer: Other: Served on advisory board. Bhatt:National Marrow Donor Program: Research Funding; Rigel Pharmaceuticals: Other; Jazz: Research Funding; Agios: Other: Personal Fees; Incyte: Other: Personal Fees, Research Funding; Takeda: Other: Personal Fees; Partner Therapeutics: Other: Personal Fees; Pfizer: Other, Research Funding; CSL Behring: Other; Tolero Pharmaceuticals: Research Funding; Oncoceutics: Other: Drug support for a trial; Partnership for health analytic research, LLC: Other: Personal Fees; Omeros: Other: Personal Fees; Abbvie: Other: Personal Fees, Research Funding. Saad:Orcabio: Other: research support; Kadmon: Other: research support; Amgen: Other: research support; Incyte Pharmaceuticals: Other: Personal Fees; Magenta Therapeutics: Other: Personal Fees. Copelan:Amgen: Membership on an entity's Board of Directors or advisory committees. Defilipp:Incyte: Research Funding; Regimmune: Research Funding; Syndax Pharmaceuticals: Consultancy. Nishihori:Karyopharm: Other: Research support to institution; Novartis: Other: Research support to institution. Weisdorf:Incyte: Research Funding; FATE Therapeutics: Consultancy.
Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS
Kim, Soyoung , Hu, Zhen‐Huan , Aljurf, Mahmoud , Beitinjaneh, Amer , Cahn, Jean‐Yves, Černý, Jan , Copelan, Edward A. , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hamilton, Betty K. , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Kamble, Rammurti T., Kindwall‐Keller, Tamila L. , Litzow, Mark R. , Rizzieri, David A. , Seo, Sachiko , Solh, Melhem , Verdonck, Leo F. , Wirk, Baldeep , Woolfrey, Ann E. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Hashmi, Shahrukh, Gadalla, Shahinaz M , Kim, Soyoung , Gupta, Vikas , Liu, Ying , Bacher, Ulrike , Cahn, Jean‐Yves , Gale, Robert Peter , George, Biju , Gerds, Aaron T. , Gergis, Usama , Lazarus, Hillard M. , Liesveld, Jane L. , Maziarz, Richard Thomas , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Szer, Jeff , Yared, Jean A. , Popat, Uday R

Mayo Clinic

Blood Advances | October 2, 2020 | Volume: 4 | Issue: 19 | Pages: 4748-4757

10.1182/bloodadvances.2020002621 | PMID 33007075 Get It

Abstract Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1− myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation–based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
Munshi, Pashna N. , Vesole, David H. , Martin, Andrew St., Dávila, Omar, Badawy, Sherif M. , Copelan, Edward A. , Kharfan‐Dabaja, Mohamed A. , Farhadfar, Nosha , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Krem, Maxwell M. , Malek, Ehsan , Meehan, Kenneth R., Murthy, Hemant S. , Olin, Rebecca L. , Schriber, Jeffrey, Seo, Sachiko , Shah, Gunjan L. , Solh, Melhem , Tay, Jason , Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , D’Souza, Anita , Farhadfar, Nosha , Hashmi, Shahrukh K , Malek, Ehsan , Kumar, Shaji K , Qazilbash, Muzaffar H , Shah, Nina , D'Souza, Anita , Murthy, Hemant S , Badawy, Sherif M , Shah, Gunjan L , Jurczyszyn, Artur , Zaucha, Jan Maciej , Agrawal, Vaibhav , Battiwalla, Minoo , Chhabra, Saurabh , Lazarus, Hillard M. , Nishihori, Taiga , Olsson, Richard F. , Hari, Parameswaran

Mayo Clinic

Cancer | September 23, 2020 | Volume: 126 | Issue: 23 | Pages: 5077-5087

10.1002/cncr.33171 | PMID 32965680 Get It

BackgroundUpfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults.MethodsThe authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression‐free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori.ResultsAn increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m2 overall, 58% of the patients aged ≥70 years received Mel at a dose of 140 mg/m2. On multivariate analysis, patients aged ≥70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1‐1.7 [P = .06]), REL (HR, 1.03; 99% CI, 0.9‐1.1 [P = 0.6]), PFS (HR, 1.06; 99% CI, 1‐1.2 [P = 0.2]), and OS (HR, 1.2; 99% CI, 1‐1.4 [P = .02]) compared with the reference group (those aged 60‐69 years). In patients aged ≥70 years, Mel administered at a dose of 140 mg/m2 was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m2, including day 100 NRM (1% [95% CI, 1%‐2%] vs 0% [95% CI, 0%‐1%]; P = .003]), 2‐year PFS (64% [95% CI, 60%‐67%] vs 69% [95% CI, 66%‐73%]; P = .003), and 2‐year OS (85% [95% CI, 82%‐87%] vs 89% [95% CI, 86%‐91%]; P = .01]), likely representing frailty.ConclusionsThe results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Brazauskas, Ruta , Tecca, Heather R. , Bo‐Subait, Stephanie, Buchbinder, David , Battiwala, Minoo, Phelan, Rachel , Broglie, Larisa , Abraham, Allistair , Keating, Amy K. , Daly, Andrew , Wirk, Baldeep , Alter, Blanche P. , Üstün, Celalettin , Freytes, César O. , Beitinjaneh, Amer , Duncan, Christine , Copelan, Edward A. , Hildebrandt, Gerhard , Murthy, Hemant S. , Auletta, Jeffery J. , Page, Kristin , Vrooman, Lynda M. , Norkin, Maxim , Byrne, Michael , Kamani, Naynesh , Rezvani, Andrew R. , Farhadfar, Nosha , Mehta, Parinda A. , Hematti, Peiman , Shaw, Peter J. , Kamble, Rammurti T., Schears, Raquel M. , Hayashi, Robert J. , Mayo, Samantha , Rotz, Seth J. , Badawy, Sherif M. , Ganguly, Siddhartha , Pavletic, Steven Z. , Prestidge, Tim , Inamoto, Yoshihiro , Shaw, Bronwen E. , Satwani, Prakash , Battiwalla, Minoo , Schears, Raquel, Murthy, Hemant S , Badawy, Sherif M , Broglie, Larisa A , Battiwalla, Minoo , Auletta, Jeffery J , Hematti, Peiman , Kahn, Justine M , Flowers, Mary E.D. , Savani, Bipin N. , George, Biju , Lazarus, Hillard M. , Myers, Kasiani , Williams, Kirsten M. , Díaz, Miguel Ángel , Bhatt, Neel S. , Olsson, Richard F. , Gale, Robert Peter , Chhabra, Saurabh , Nishihori, Taiga , Agrawal, Vaibhav , Hogan, William J.

Mayo Clinic

Blood Advances | May 12, 2020 | Volume: 4 | Issue: 9 | Pages: 2084-2094

10.1182/bloodadvances.2019000839 | PMID 32396620 Get It

Abstract We examined the risk of subsequent neoplasms (SNs) and late mortality in children and adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile range, 1-11; range, &lt;1 to 20) from the Center for International Blood and Marrow Transplant Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with expected rates in the general population. Median follow-up of survivors was 7.8 years. Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95% CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%). Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%); for other NMDs, incidence was &lt;1%. Hematologic (27%), oropharyngeal (25%), and skin cancers (13%) were most common. Leukemia risk was highest in the first 5 years posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after 5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of SN development was highest in patients with FA and marrow failure syndromes, highlighting the need for long-term posttransplantation surveillance in this population.
Survival following allogeneic transplant in patients with myelofibrosis
Gowin, Krisstina , Ballen, Karen K. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Ali, Haris , Arcasoy, Murat O. , Devlin, Rebecca, Coakley, Maria , Gerds, Aaron T. , Jain, Tania , Kandarpa, Malathi , Komrokji, Rami S. , Luber, Kierstin, Michaelis, Laura C. , Patches, Sarah, Pariser, Ashley, Rampal, Raajit K. , Stein, Brady L. , Verstovšek, Srđan , Wadleigh, Martha , Aljurf, Mahmoud , Avalos, Belinda R. , Bashey, Asad, Beitinjaneh, Amer , Černý, Jan , Copelan, Edward A. , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Kharfan‐Dabaja, Mohamed A. , Kindwall‐Keller, Tamila L. , Kröger, Nicolaus , Litzow, Mark R. , Marks, David I. , Nathan, Sunita , Pawarode, Attaphol , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Tamari, Roni , Verdonck, Leo F. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Kroger, Nicolaus , Davenport, Ashley Pariser , Gerds, Aaron T , Jain, Tania , Gadalla, Shahinaz M , Verstovsek, Srdan , Komrokji, Rami S , Kroger, Nicolaus , Kröger, Nicolaus , Green, Michael, Gupta, Vikas , Hobbs, Gabriela , Kuykendall, Andrew , Masárová, Lucia , Talpaz, Moshe , Agrawal, Vaibhav , Díaz, Miguel Ángel , Bacher, Ulrike , Chhabra, Saurabh , Cutler, Corey S. , Grunwald, Michael R. , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Yared, Jean A. , Popat, Uday R , Mesa, Ruben A.

Mayo Clinic

Blood Advances | May 8, 2020 | Volume: 4 | Issue: 9 | Pages: 1965-1973

10.1182/bloodadvances.2019001084 | PMID 32384540 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P &lt; .0001; DIPSS-Int-2 and higher: HR, 0.39, P &lt; .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P &lt; .0001; DIPSS-Int-2 and higher: HR, 2.55, P &lt; .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.